Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Two Formulations of Lepodisiran in Healthy Participants
NCT05932446Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2023
- Primary completion
- Nov 2023
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lepodisiran in lipoprotein disorders and elevated lipoprotein(a) (Lp(a)) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve From Time Zero to the Last Timepoint with Measurable Concentration, Area Under the Concentration Versus Time Curve From Time Zero to Infinity and 1 more. Started Jun 2023; status: completed.
02
Drugs
lepodisiran
03
Conditions
lipoprotein disorderselevated lipoprotein(a) (Lp(a))
Beyond the preview
Go deeper on NCT05932446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05932446.